Key facts
- It has raised $3.8M; the latest was Seed Round ($3.0M) in May 2025.
- Notable investors include Newsight Tech Angels, NuFund Venture Group, TCA Venture Group.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Eyegenex
- ·The full record, as it builds
Funding rounds
No funding rounds for Eyegenex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eyegenex
Developer of therapeutics designed to address unmet needs in ophthalmic diseases. The company offers a pipeline of drug candidates targeting glaucoma, diabetic retinopathy, and other vision-threatening conditions, with the potential to prevent blindness and improve patient outcomes.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Employees
- 3
- Website
- eyegenex.com/
- Ownership
- Privately Held (backing)
Eyegenex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eyegenex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eyegenex in its N-PORT filings yet. We sweep new filings monthly.